Literature DB >> 22281939

A founder mutation in LEPRE1 carried by 1.5% of West Africans and 0.4% of African Americans causes lethal recessive osteogenesis imperfecta.

Wayne A Cabral1, Aileen M Barnes, Adebowale Adeyemo, Kelly Cushing, David Chitayat, Forbes D Porter, Susan R Panny, Fizza Gulamali-Majid, Sarah A Tishkoff, Timothy R Rebbeck, Serigne M Gueye, Joan E Bailey-Wilson, Lawrence C Brody, Charles N Rotimi, Joan C Marini.   

Abstract

PURPOSE: Deficiency of prolyl 3-hydroxylase 1, encoded by LEPRE1, causes recessive osteogenesis imperfecta (OI). We previously identified a LEPRE1 mutation exclusively in African Americans and contemporary West Africans. We hypothesized that this allele originated in West Africa and was introduced to the Americas with the Atlantic slave trade. We aimed to determine the frequency of carriers for this mutation among African Americans and West Africans, and the mutation origin and age.
METHODS: Genomic DNA was screened for the mutation using PCR and restriction digestion, and a custom TaqMan genomic single-nucleotide polymorphism assay. The mutation age was estimated using microsatellites and short tandem repeats spanning 4.2 Mb surrounding LEPRE1 in probands and carriers.
RESULTS: Approximately 0.4% (95% confidence interval: 0.22-0.68%) of Mid-Atlantic African Americans carry this mutation, estimating recessive OI in 1/260,000 births in this population. In Nigeria and Ghana, 1.48% (95% confidence interval: 0.95-2.30%) of unrelated individuals are heterozygous carriers, predicting that 1/18,260 births will be affected with recessive OI, equal to the incidence of de novo dominant OI. The mutation was not detected in Africans from surrounding countries. All carriers shared a haplotype of 63-770 Kb, consistent with a single founder for this mutation. Using linkage disequilibrium analysis, the mutation was estimated to have originated between 650 and 900 years before present (1100-1350 CE).
CONCLUSION: We identified a West African founder mutation for recessive OI in LEPRE1. Nearly 1.5% of Ghanians and Nigerians are carriers. The estimated age of this allele is consistent with introduction to North America via the Atlantic slave trade (1501-1867 CE).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22281939      PMCID: PMC3393768          DOI: 10.1038/gim.2011.44

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  27 in total

1.  Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.

Authors:  C M Zeigler-Johnson; A H Walker; B Mancke; E Spangler; M Jalloh; S McBride; A Deitz; S B Malkowicz; D Ofori-Adjei; S M Gueye; T R Rebbeck
Journal:  Hum Hered       Date:  2002       Impact factor: 0.444

2.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

3.  Carrier frequency of the RSH/Smith-Lemli-Opitz IVS8-1G>C mutation in African Americans.

Authors:  Brooke S Wright; Ngozi A Nwokoro; Christopher A Wassif; Forbes D Porter; John S Waye; Barry Eng; Małgorzata J M Nowaczyk
Journal:  Am J Med Genet A       Date:  2003-07-01       Impact factor: 2.802

Review 4.  Using linked markers to infer the age of a mutation.

Authors:  B Rannala; G Bertorelle
Journal:  Hum Mutat       Date:  2001-08       Impact factor: 4.878

5.  CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta.

Authors:  Roy Morello; Terry K Bertin; Yuqing Chen; John Hicks; Laura Tonachini; Massimiliano Monticone; Patrizio Castagnola; Frank Rauch; Francis H Glorieux; Janice Vranka; Hans Peter Bächinger; James M Pace; Ulrike Schwarze; Peter H Byers; MaryAnn Weis; Russell J Fernandes; David R Eyre; Zhenqiang Yao; Brendan F Boyce; Brendan Lee
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

6.  Osteogenesis imperfecta and non-accidental injury.

Authors:  H Minnis; R Ramsay; P Ewije; C Kumar
Journal:  Br J Psychiatry       Date:  1995-06       Impact factor: 9.319

7.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

Review 8.  Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta.

Authors:  Joan C Marini; Wayne A Cabral; Aileen M Barnes
Journal:  Cell Tissue Res       Date:  2009-10-28       Impact factor: 5.249

9.  Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease.

Authors:  L M Ward; F Rauch; R Travers; G Chabot; E M Azouz; L Lalic; P J Roughley; F H Glorieux
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

10.  A genome-wide association study of hypertension and blood pressure in African Americans.

Authors:  Adebowale Adeyemo; Norman Gerry; Guanjie Chen; Alan Herbert; Ayo Doumatey; Hanxia Huang; Jie Zhou; Kerrie Lashley; Yuanxiu Chen; Michael Christman; Charles Rotimi
Journal:  PLoS Genet       Date:  2009-07-17       Impact factor: 5.917

View more
  22 in total

1.  Clinical utility gene card for: osteogenesis imperfecta.

Authors:  Fleur S van Dijk; Raymond Dalgleish; Fransiska Malfait; Alessandra Maugeri; Agnieszka Rusinska; Oliver Semler; Sofie Symoens; Gerard Pals
Journal:  Eur J Hum Genet       Date:  2012-09-26       Impact factor: 4.246

2.  Molecular Consequences of the SERPINH1/HSP47 Mutation in the Dachshund Natural Model of Osteogenesis Imperfecta.

Authors:  Uschi Lindert; Mary Ann Weis; Jyoti Rai; Frank Seeliger; Ingrid Hausser; Tosso Leeb; David Eyre; Marianne Rohrbach; Cecilia Giunta
Journal:  J Biol Chem       Date:  2015-05-24       Impact factor: 5.157

Review 3.  IFITM5 mutations and osteogenesis imperfecta.

Authors:  Nobutaka Hanagata
Journal:  J Bone Miner Metab       Date:  2015-06-02       Impact factor: 2.626

4.  Molecular properties and fibril ultrastructure of types II and XI collagens in cartilage of mice expressing exclusively the α1(IIA) collagen isoform.

Authors:  Audrey McAlinden; Geoffrey Traeger; Uwe Hansen; Mary Ann Weis; Soumya Ravindran; Louisa Wirthlin; David R Eyre; Russell J Fernandes
Journal:  Matrix Biol       Date:  2013-10-07       Impact factor: 11.583

Review 5.  Osteogenesis imperfecta due to mutations in non-collagenous genes: lessons in the biology of bone formation.

Authors:  Joan C Marini; Adi Reich; Simone M Smith
Journal:  Curr Opin Pediatr       Date:  2014-08       Impact factor: 2.856

Review 6.  The African diaspora: history, adaptation and health.

Authors:  Charles N Rotimi; Fasil Tekola-Ayele; Jennifer L Baker; Daniel Shriner
Journal:  Curr Opin Genet Dev       Date:  2016-09-16       Impact factor: 5.578

7.  Evidence for a de novo, dominant germ-line mutation causative of osteogenesis imperfecta in two Red Angus calves.

Authors:  Jessica L Petersen; Shauna M Tietze; Rachel M Burrack; David J Steffen
Journal:  Mamm Genome       Date:  2019-02-20       Impact factor: 2.957

Review 8.  New genes in bone development: what's new in osteogenesis imperfecta.

Authors:  Joan C Marini; Angela R Blissett
Journal:  J Clin Endocrinol Metab       Date:  2013-06-14       Impact factor: 5.958

9.  The development of a mature collagen network in cartilage from human bone marrow stem cells in Transwell culture.

Authors:  Alan D Murdoch; Timothy E Hardingham; David R Eyre; Russell J Fernandes
Journal:  Matrix Biol       Date:  2015-10-30       Impact factor: 11.583

Review 10.  A brilliant breakthrough in OI type V.

Authors:  S Lazarus; P Moffatt; E L Duncan; G P Thomas
Journal:  Osteoporos Int       Date:  2013-09-13       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.